7-chloro-5-cyclohexylpyrazolo[1,5-a]pyrimidine | 189018-71-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 7-chloro-5-cyclohexylpyrazolo[1,5-a]pyrimidine
• CAS: 189018-71-1
• 化学式: C₁₂H₁₄ClN₃
• 分子量: 235.716
• InChiKey: MTYZFTARXNBOGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1671962A1

  公开（公告）日：2006-06-21

  The compound represented by the general formula (I): wherein, a fused ring AB represents a 5- to 10-membered fused heterocyclic ring; R1 represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) an oxo group, (5) an optionally protected hydroxyl group, (6) an optionally protected carboxyl group, (7) an optionally protected amino group, (8) a cyclic group which may have a substituent (s), (9) an aliphatic hydrocarbon group which may have a substituent (s), or (10) an optionally protected thiol group; n represents 0 or an integer of 1 to 8; provided that n represents an integer of not less than 2, plural R1 are the same or different; a salt thereof, a solvate thereof or a prodrug thereof has a kinase(especially c-Jun N-terminalkinase) inhibitory activity and an inhibitory activity of a function of AP-1 as a transcription factor, it is useful as a preventive and/or therapeutic agent for a for example, a diabetes of metabolic disease, etc., a rheumatoid arthritis of inflammatory, etc.

  化合物的一般式（I）：其中，融合环AB代表一个5-至10-成员的融合杂环；R1代表（1）氢原子，（2）卤素原子，（3）氰基，（4）氧基，（5）可选保护的羟基，（6）可选保护的羧基，（7）可选保护的氨基，（8）可能具有取代基的环状基团，（9）可能具有取代基的脂肪烃基团或（10）可选保护的硫醇基团; n代表0或1至8的整数; 假设n代表不小于2的整数，则复数R1相同或不同;其盐，溶剂化物或前药具有激酶（尤其是c-Jun N末端激酶）抑制活性和AP-1作为转录因子的功能抑制活性，因此可用作预防和/或治疗代谢疾病（例如糖尿病等）和炎症性风湿性关节炎等的药物。
• Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
  申请人：Guzi J. Timothy

  公开号：US20070281951A1

  公开（公告）日：2007-12-06

  In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or compositions.

  在其许多实施例中，本发明提供了一种新型的嘧唑并[1,5-a]嘧啶类化合物作为细胞周期依赖性激酶抑制剂，制备这种化合物的方法，含有一种或多种此类化合物的组合物，制备包含一种或多种此类化合物的制药配方的方法，并使用这种化合物或组合物进行一种或多种与CDK相关的疾病的治疗、预防、抑制或改善的方法。
• Pyrazolopyrimidines as cyclin dependent kinase inhibitors
  申请人：Guzi J. Timothy

  公开号：US20070225270A1

  公开（公告）日：2007-09-27

  In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一种新型的嘧唑并[1,5-a]嘧啶化合物类作为细胞周期蛋白依赖性激酶的抑制剂，制备这种化合物的方法，含有一种或多种这种化合物的制药组合物，制备包含一种或多种这种化合物的制药制剂的方法，以及使用这种化合物或制药组合物治疗、预防、抑制或缓解与CDKs相关的一种或多种疾病的方法。
• Novel fused heterocyclic compound and use thereof
  申请人：Yoshizawa Toshio

  公开号：US20070060595A1

  公开（公告）日：2007-03-15

  The compound represented by the general formula (I): wherein, a fused ring AB represents a 5- to 10-membered fused heterocyclic ring; R 1 represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) an oxo group, (5) an optionally protected hydroxyl group, (6) an optionally protected carboxyl group, (7) an optionally protected amino group, (8) a cyclic group which may have a substituent (s), (9) an aliphatic hydrocarbon group which may have a substituent (s), or (10) an optionally protected thiol group; n represents 0 or an integer of 1 to 8; provided that n represents an integer of not less than 2, plural R 1 are the same or different; a salt thereof, a solvate thereof or a prodrug thereof has a kinase (especially c-Jun N-terminal kinase) inhibitory activity and an inhibitory activity of a function of AP-1 as a transcription factor, it is useful as a preventive and/or therapeutic agent for a for example, a diabetes of metabolic disease, etc., a rheumatoid arthritis of inflammatory, etc.

  化合物的一般式(I)表示的化合物：其中，融合环AB表示一个5-至10-成员的融合杂环；R1表示（1）氢原子，（2）卤原子，（3）氰基，（4）氧代基，（5）可选保护的羟基，（6）可选保护的羧基，（7）可选保护的氨基，（8）可能具有取代基（s）的环状基团，（9）可能具有取代基（s）的脂肪烃基团，或（10）可选保护的硫醇基团；n表示0或1至8的整数；但是，如果n表示不少于2的整数，则复数R1相同或不同；其盐、溶剂化物或前药具有激酶（特别是c-Jun N末端激酶）抑制活性和AP-1作为转录因子的功能抑制活性，因此它对于例如代谢性疾病的糖尿病等，炎症性的类风湿性关节炎等的预防和/或治疗剂是有用的。
• ANALGESICS
  申请人：OTSUKA PHARMACEUTICAL FACTORY, INC.

  公开号：EP0795555A1

  公开（公告）日：1997-09-17

  The invention provides an analgesic composition comprising as an active ingredient at least one pyrazolo[1,5-a]pyrimidine derivative of the following formula (1): wherein R11 represents hydrogen, lower alkyl, pyridyl, furyl, thienyl, phenyl optionally having lower alkyl or phenylthio as a substituent, N-(lower)alkylpyrrolyl or pyrazinyl; R12 represents hydrogen, halogen, phenyl, phenyl having halogen, phenylthio or trifluoromethyl as a substituent, phenyl having trifluoromethyl and nitro as substituents, or phenyl having lower alkoxy and phenylthio as substituents; R13 represents hydrogen, lower alkyl optionally having oxo, ethylenedioxy, lower alkanoyloxy, lower alkoxy, lower alkylthio, carboxyl, halogen or thienyl as a substituent, lower alkenyl, cycloalkyl, or phenyl optionally having 1 to 3 substituents selected from the group consisting of lower alkyl, halogen and lower alkoxy, furyl or thienyl; R14 represents hydrogen, carboxyl, lower alkoxycarbonyl, nitro, halogen, or lower alkyl having lower alkoxycarbonyl or the residue of an alkali metal salt of carboxylic acid as a substituent; R13 and R14 may conjointly form lower alkylene; R15 represents hydrogen, alkali metal, lower alkyl, phenyl optionally having 1 to 3 substituents selected from the group consisting of lower alkyl and lower alkoxy, pyridyl optionally having lower alkyl or halogen as a substituent, quinolyl or isoquinolyl; and A represents a single bond or lower alkylene. This composition exhibits potent analgesic activity and is effective for alleviating various types of pain such as postoperative pain.

  本发明提供了一种镇痛组合物，其活性成分包括至少一种下式（1）的吡唑并[1,5-a]嘧啶衍生物： 其中 R11 代表氢、低级烷基、吡啶基、呋喃基、噻吩基、任选以低级烷基或苯硫基为取代基的苯基、N-(低级)烷基吡咯基或吡嗪基；R12 代表氢、卤素、苯基、以卤素、苯硫基或三氟甲基为取代基的苯基、以三氟甲基和硝基为取代基的苯基或以低级烷氧基和苯硫基为取代基的苯基；R13 代表氢、任选具有氧代、亚乙基氧基、低级烷酰氧基、低级烷氧基、低级烷硫基、羧基、卤素或噻吩基作为取代基的低级烷基、任选具有 1 至 3 个选自低级烷基、卤素和低级烷氧基、呋喃基或噻吩基组成的取代基的环烷基或苯基；R14 代表氢、羧基、低级烷氧基羰基、硝基、卤素或具有低级烷氧基羰基或羧酸碱金属盐残基作为取代基的低级烷基；R13 和 R14 可共同形成低级亚烷基；R15 代表氢、碱金属、低级烷基、可选择具有 1 至 3 个取代基的苯基，这些取代基可从低级烷基和低级烷氧基、可选择具有低级烷基或卤素作为取代基的吡啶基、喹啉基或异喹啉基组成的组中选出；以及 A 代表单键或低级亚烷基。这种组合物具有强效镇痛活性，可有效缓解各种疼痛，如术后疼痛。